|Day's Range||282.70 - 282.70|
|52 Week Range||233.00 - 285.50|
|PE Ratio (TTM)||237.96|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
In 2016, Pfizer’s (PFE) Medrol reported revenues of ~$450 million, which represented a ~12% rise on a YoY (year-over-year) basis.
While Pfizer, Inc.'s (PFE) new drugs like Ibrance and acquisitions like Hospira are likely to drive sales in Q2, genericization of key drugs, pricing pressure and rising competition will hurt sales.
The Zacks Analyst Blog Highlights: Oracle, Pfizer, Abbott, Alphabet and Schlumberger